539 related articles for article (PubMed ID: 24590565)
1. Combined oral contraceptives: venous thrombosis.
de Bastos M; Stegeman BH; Rosendaal FR; Van Hylckama Vlieg A; Helmerhorst FM; Stijnen T; Dekkers OM
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010813. PubMed ID: 24590565
[TBL] [Abstract][Full Text] [Related]
2. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis.
Stegeman BH; de Bastos M; Rosendaal FR; van Hylckama Vlieg A; Helmerhorst FM; Stijnen T; Dekkers OM
BMJ; 2013 Sep; 347():f5298. PubMed ID: 24030561
[TBL] [Abstract][Full Text] [Related]
3. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
[TBL] [Abstract][Full Text] [Related]
4. Oral contraceptives containing drospirenone for premenstrual syndrome.
Lopez LM; Kaptein AA; Helmerhorst FM
Cochrane Database Syst Rev; 2012 Feb; (2):CD006586. PubMed ID: 22336820
[TBL] [Abstract][Full Text] [Related]
5. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
6. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9.
Lidegaard Ø; Nielsen LH; Skovlund CW; Skjeldestad FE; Løkkegaard E
BMJ; 2011 Oct; 343():d6423. PubMed ID: 22027398
[TBL] [Abstract][Full Text] [Related]
7. Drospirenone: high risk of venous thrombosis.
Prescrire Int; 2011 Feb; 20(113):43-5. PubMed ID: 21488592
[TBL] [Abstract][Full Text] [Related]
8. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: The role of the progestogen type and estrogen dose.
Oedingen C; Scholz S; Razum O
Thromb Res; 2018 May; 165():68-78. PubMed ID: 29573722
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
Dragoman MV; Tepper NK; Fu R; Curtis KM; Chou R; Gaffield ME
Int J Gynaecol Obstet; 2018 Jun; 141(3):287-294. PubMed ID: 29388678
[TBL] [Abstract][Full Text] [Related]
11. [Hormonal contraception and vascular risk: CNGOF Contraception Guidelines].
Plu-Bureau G; Sabbagh E; Hugon-Rodin J
Gynecol Obstet Fertil Senol; 2018 Dec; 46(12):823-833. PubMed ID: 30389542
[TBL] [Abstract][Full Text] [Related]
12. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
Lancet; 1995 Dec; 346(8990):1582-8. PubMed ID: 7500749
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolic disease and combined oral contraceptives: A re-analysis of the MediPlus database.
Todd J; Lawrenson R; Farmer RD; Williams TJ; Leydon GM
Hum Reprod; 1999 Jun; 14(6):1500-5. PubMed ID: 10357966
[TBL] [Abstract][Full Text] [Related]
14. Use of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case-control analysis using German claims data.
Schink T; Princk C; Braitmaier M; Haug U
BJOG; 2022 Dec; 129(13):2107-2116. PubMed ID: 35876787
[TBL] [Abstract][Full Text] [Related]
15. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
[TBL] [Abstract][Full Text] [Related]
16. Hormonal contraception and risk of venous thromboembolism: national follow-up study.
Lidegaard Ø; Løkkegaard E; Svendsen AL; Agger C
BMJ; 2009 Aug; 339():b2890. PubMed ID: 19679613
[TBL] [Abstract][Full Text] [Related]
17. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.
van Hylckama Vlieg A; Helmerhorst FM; Vandenbroucke JP; Doggen CJ; Rosendaal FR
BMJ; 2009 Aug; 339():b2921. PubMed ID: 19679614
[TBL] [Abstract][Full Text] [Related]
18. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
Endrikat J; Müller U; Düsterberg B
Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
[TBL] [Abstract][Full Text] [Related]
19. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
Koetsawang S; Charoenvisal C; Banharnsupawat L; Singhakovin S; Kaewsuk O; Punnahitanont S
Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
[TBL] [Abstract][Full Text] [Related]
20. Combined oral contraceptive pills for treatment of acne.
Arowojolu AO; Gallo MF; Lopez LM; Grimes DA
Cochrane Database Syst Rev; 2012 Jul; (7):CD004425. PubMed ID: 22786490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
